论文部分内容阅读
目的探讨尿激酶溶栓联合丁苯酞氯化钠治疗急性脑缺血的临床疗效。方法选择2012年1月至2014年6月急性脑缺血患者90例,随机分为两组,每组45例。对照组入院后予以降糖、控制血压、调脂、改善脑代谢与血液循环、抗血小板聚集等治疗措施,发病4.5 h内静脉滴注尿激酶;观察组在对照组基础上加用丁苯酞氯化钠注射液,比较两组疗效。结果总有效率观察组为93.3%,对照组为62.2%,两组比较差异有统计学意义(P<0.05);不良反应率观察组为11.0%,对照组为6.6%,两组比较差异未见统计学意义(P>0.05)。结论尿激酶联合丁苯酞氯化钠治疗急性脑缺血可发挥明显积极作用,与单纯尿激酶溶栓治疗相比效果得到强化,安全性高。
Objective To investigate the clinical efficacy of urokinase thrombolysis combined with sodium butyrate phthalate in the treatment of acute cerebral ischemia. Methods Ninety patients with acute cerebral ischemia from January 2012 to June 2014 were randomly divided into two groups (45 in each group). Control group after admission to be hypoglycemic, control blood pressure, lipid regulation, improve brain metabolism and blood circulation, anti-platelet aggregation and other treatment measures, the incidence of intravenous infusion of urokinase within 4.5 h; the observation group in the control group based on the use of butylphthalide Sodium chloride injection, the two groups were compared. Results The total effective rate was 93.3% in the observation group and 62.2% in the control group, with significant difference between the two groups (P <0.05); adverse reaction rate was 11.0% in the observation group and 6.6% in the control group, with no significant difference between the two groups See statistical significance (P> 0.05). Conclusions Urokinase combined with sodium butyrate phthalate in the treatment of acute cerebral ischemia can play a significant positive effect, compared with simple urokinase thrombolytic therapy, the effect is enhanced and safe.